Thomas G. Boyer, Ph.D.

Slide28 boyer


Dr. Thomas Boyer lab's long-term goal is to elucidate basic mechanisms of eukaryotic transcription control and clarify how these controls are subverted during oncogenesis. 

Ultimately, we hope to use such information to identify points of oncogenic susceptibility within the cell and thus identify potential targets for pharmacologic intervention. We employ biochemical, molecular, and cell biological approaches to study the regulation of eukaryotic RNA polymerase II transcription.

Selected Publications

Vulto-van Silfhout AT, de Vries BB, van Bon BW, Hoischen A, Ruiterkamp-Versteeg M, Gilissen C, Gao F, van Zwam M, Harteveld CL, van Essen AJ, Hamel BC, Kleefstra T, Willemsen MA, Yntema HG, van Bokhoven H, Brunner HG, Boyer TG, de Brouwer AP.  Mutations in MED12 cause X-linked Ohdo syndrome. Am J Hum Genet. 2013 Mar 7;92(3):401-6.

Gu S, Boyer TG, Naski MC. Basic helix-loop-helix transcription factor Twist1 inhibits transactivator function of master chondrogenic regulator Sox9. J Biol Chem. 2012 Jun 15;287(25):21082-92.

Zhou H, Spaeth JM, Kim NH, Xu X, Friez MJ, Schwartz CE, Boyer TG. MED12 mutations link intellectual disability syndromes with dysregulated GLI3-dependent Sonic Hedgehog signaling. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19763-8.

Xu X, Zhou H, Boyer TG. Mediator is a transducer of amyloid-precursor-protein-dependent nuclear signalling. EMBO Rep. 2011 Mar;12(3):216-22.

Spaeth JM, Kim NH, Boyer TG. Mediator and human disease. Semin Cell Dev Biol. 2011 Sep;22(7):776-87.

Molecular Medicine


Ph.D., Biochemistry, State University of New York at Buffalo, 1990

M.S., Biology, Frostburg State University, 1983

M.S., Wildlife/Fisheries Management, Frostburg State University, 1983



Phone: (210) 562-4151

Research Profile
More Info...